| __timestamp | CRISPR Therapeutics AG | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 1860000 |
| Thursday, January 1, 2015 | 13403000 | 2963000 |
| Friday, January 1, 2016 | 31056000 | 6961000 |
| Sunday, January 1, 2017 | 35845000 | 11779000 |
| Monday, January 1, 2018 | 48294000 | 13697000 |
| Tuesday, January 1, 2019 | 63488000 | 15749000 |
| Wednesday, January 1, 2020 | 88208000 | 18638000 |
| Friday, January 1, 2021 | 102802000 | 27196000 |
| Saturday, January 1, 2022 | 102464000 | 31739000 |
| Sunday, January 1, 2023 | 76162000 | 33491000 |
| Monday, January 1, 2024 | 72977000 |
Unveiling the hidden dimensions of data
In the rapidly evolving biotech sector, understanding financial trends is crucial. Over the past decade, CRISPR Therapeutics AG and Protagonist Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, CRISPR Therapeutics AG's SG&A costs surged by over 1,400%, peaking in 2021. This reflects their aggressive expansion and investment in groundbreaking gene-editing technologies. In contrast, Protagonist Therapeutics, Inc. experienced a more modest increase of approximately 1,700%, with a steady rise in expenses, indicating a strategic scaling of operations. Notably, 2023 saw a decline in CRISPR's expenses by about 26%, possibly signaling a shift towards operational efficiency. Meanwhile, Protagonist's expenses continued to climb, reaching their highest point. These trends highlight the differing strategies and market responses of these biotech innovators, offering valuable insights for investors and industry analysts alike.
Operational Costs Compared: SG&A Analysis of Pfizer Inc. and Protagonist Therapeutics, Inc.
Biogen Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Protagonist Therapeutics, Inc.
Incyte Corporation or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or CRISPR Therapeutics AG
Alpine Immune Sciences, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Xenon Pharmaceuticals Inc.
Comparing SG&A Expenses: CRISPR Therapeutics AG vs Wave Life Sciences Ltd. Trends and Insights
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Galapagos NV